The epidemiological and clinical study of patients with clostridium difficile enterocolitis in Varna, Bulgaria
- 作者: Lyutsova E.D.1, Gospodinova M.D.1
-
隶属关系:
- Medical University Prof. Dr. Paraskev Stoyanov
- 期: 卷 12, 编号 2 (2022)
- 页面: 366-372
- 栏目: ORIGINAL ARTICLES
- URL: https://journal-vniispk.ru/2220-7619/article/view/119131
- DOI: https://doi.org/10.15789/2220-7619-TEA-1669
- ID: 119131
如何引用文章
全文:
详细
Introduction. Clostridium difficile infections (CDI) remain a global health concern. Currently, no unified approach to the diagnostics and determining severity of these infections despite their high urgency throughout the world was proposed. The aim of the study is to identify risk factors for CDI, investigate clinical and epidemiological features of the disease course and potential for using the ATLAS scale to assess its severity. Materials and methods. 36 CDI patients hospitalized at the Infectious Disease Clinic of Varna were analyzed during the period from January 2018 until June 2019. Clinical and epidemiologic study was conducted. The diagnosis was made by using a rapid immunochromatographic test; CDI patient stratification was performed by ATLAS scoring system. Results and discussion. Within the aforementioned period, 1100 patients were hospitalized at the Infectious Disease Clinic of Varna, and CDIs were reported in 3,3% of cases. The most affected were elderly individuals (the mean age was 69,8±16,4 years old) most of whom were females (92%) with only 6% of males. The following risk factors were investigated: comorbidities — 32 patients (88,89%), recent hospitalization — 19 patients (52,78%), antibiotic use — 31 patients (86,11%). Twenty-four patients (66,67%, ATLAS score ≤ 4 points) had mild CDI, whereas moderate form of CDI was observed in 12 patients (33,33%). No severe CDI or death were observed. The characteristic clinical presentation included fever, diarrhea and abdominal cramping. The treatment was implemented according to the national and international recommendations by using oral Metronidazole for 11 patients (30,56%), Vancomycin — for 12 patients (33,33%), or both — for 13 patients (36,11%). Conclusion. Patients at risk with symptoms of enterocolitis and a history of antibiotic use or hospitalizations should be screened for the presence of toxin-forming strains of Clostridium difficile. According to the European Centre for Disease Prevention (ECDC) the diagnostic yield of CDI may be increased by using two-step protocol, whereas the ATLAS score system may be a useful tool for routine evaluation of patients with CDI.
作者简介
Ekaterina Lyutsova
Medical University Prof. Dr. Paraskev Stoyanov
Email: evalkova83@gmail.com
ORCID iD: 0000-0001-7692-3934
Assistant Professor, Department of Infectious Diseases, Parasitology and Dermatovenereology
保加利亚, 9000, Varna, Tsar Osvoboditel str., 100M. Gospodinova
Medical University Prof. Dr. Paraskev Stoyanov
编辑信件的主要联系方式.
Email: dr_m_gospodinova@abv.bg
Professor, PhD, MD (Medicine), Department of Infectious Diseases, Parasitology and Dermatovenereology
保加利亚, 9000, Varna, Tsar Osvoboditel str., 100参考
- Campbell K.A., Phillips M.S., Stachel A., Bosco J.A III, Mehta S.A. Incidence and risk factors for hospital-acquired Clostridium diffcile infection among inpatients in an orthopaedic tertiary care hospital. J. Hosp. Infect., 2013, vol. 83, no. 2, pp. 146–149. doi: 10.1016/j.jhin.2012.11.009
- Crobach M., Vernon J.J., Loo V.G., Kong L.Y., Pechine S., Wilcox M.H., Kuijper E.J. Understanding Clostridium difficile colonization. Clin. Microbiol. Rev., 2018, vol. 31, no. 2: e00021-17. doi: 10.1128/CMR.00021-17
- Czepiel J., Dróżdż M., Pituch H., Kuijper E.J., Perucki W., Mielimonka A., Goldman S., Wultanska D., Garlicki A., Biesiada G. Clostridium difficile infection: review. Eur. J. Clin. Microbiol. Infect. Dis., 2019, vol. 38, no. 7, pp. 1211–1221. doi: 10.1007/s10096-019-03539-6
- Davidovics Z.H., Michail S., Nicholson M.R., Kociolek L.K., Pai N., Hansen R., Schwerd T., Maspons A., Shamir R., Szajewska H., Thapar N., de Meij T., Mosca A., Vandenplas Y., Kahn S.A., Kellermayer R.; FMT Special Interest Group of the North American Society of Pediatric Gastroenterology Hepatology, Nutrition, the European Society for Pediatric Gastroenterology Hepatology, Nutrition. Fecal microbiota transplantation for recurrent Clostridium difficile infection and other conditions in children: a joint position paper from the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J. Pediatr. Gastroenterol. Nutr., 2019, vol. 68, no. 1, pp. 130–143. doi: 10.1097/MPG.0000000000002205
- Davies K.A., Longshaw C., Davis G.L., Bouza E., Barbut F., Barna Z., Delmée M., Fitzpatrick F., Ivanova K., Kuijper E.J., Macovei I.S., Mentula S., Mastrantonio P., von Müller L., Oleastro M., Petinaki E., Pituch H., Norén T., Nováková E., Nyč O., Rupnik M., Schmid D., Wilcox M.H. Underdiagnosis of Clostridium difficile across Europe: the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID). Lancet Infect. Dis., 2014, vol. 14, no. 12, pp. 1208–1219. doi: 10.1016/S1473-3099(14)70991-0
- Debast S.B., Bauer M.P., Kuijper E.J.; European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin. Microbiol. Infect., 2014, vol. 20, no. 2, pp. 1–26. doi: 10.1111/1469-0691.12418
- Deshpande A., Pasupuleti V., Thota P., Pant C., Rolston D.D., Hernandez A.V., Donskey C.J., Fraser T.G. Risk factors for recurrent Clostridium diffcile infection: a systematic review and meta-analysis. Infect. Control. Hosp. Epidemiol., 2015, vol. 36, no. 4, pp. 452–460. doi: 10.1017/ice.2014.88
- ECDC. Laboratory procedures for diagnosis and typing of human Clostridium difficile infection. Stockholm: ECDC, 2018. 47 p. doi: 10.2900/04291
- Eze P., Balsells E., Kyaw M.H., Nair H. Risk factors for Clostridium difficile infections — an overview of the evidence base and challenges in data synthesis. J. Glob. Health., 2017, vol. 7, no. 1: 010417. doi: 10.7189/jogh.07.010417
- Furuya-Kanamori L., Stone J.C., Clark J., McKenzie S.J., Yakob L., Paterson D.L., Riley T.V., Doi S.A., Clements A.C. Comorbidities, exposure to medications, and the risk of community-acquired Clostridium diffcile infection: a systematic review and meta-analysis. Infect. Control Hosp. Epidemiol., 2015, vol. 36, no. 2, pp. 132–141. doi: 10.1017/ice.2014.39
- Johnson S., Louie T.J., Gerding D.N., Cornely O.A., Chasan-Taber S., Fitts D., Gelone S.P., Broom C., Davidson D.M.; Polymer Alternative for CDI Treatment (PACT) investigators. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin. Infect. Dis., 2014, vol. 59, no. 3, pp. 345–354. doi: 10.1093/cid/ciu313
- Kelly C.P. Can we identify patients at high risk of recurrent Clostridium difcile infection? Clin. Microbiol. Infect., 2012, 18, no. 6, pp. 21–27. doi: 10.1111/1469-0691.12046
- Lessa F.C., Gould C.V., McDonald L.C. Current status of Clostridium diffcile infection epidemiology. Clin. Infect. Dis., 2012, vol. 55, no. 2, pp. 65–70. doi: 10.1093/cid/cis319
- Lessa F.C., Mu Y., Bamberg W.M., Beldavs Z.G., Dumyati G.K., Dunn J.R., Farley M.M., Holzbauer S.M., Meek J.I., Phipps E.C., Wilson L.E., Winston L.G., Cohen J.A., Limbago B.M., Fridkin S.K., Gerding D.N., McDonald L.C. Burden of Clostridium difficile infection in the United States. N. Engl. J. Med., 2015, vol. 372, no. 9, pp. 825–834. doi: 10.1056/NEJMoa1408913
- McDonald L.C., Gerding D.N., Johnson S., Bakken J.S., Carroll K.C., Coffin S.E., Dubberke E.R., Garey K.W., Gould C.V., Kelly C., Loo V., Shaklee Sammons J., Sandora T.J., Wilcox M.H. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin. Infect. Dis., 2018, vol. 66, no. 7: cix1085. doi: 10.1093/cid/cix1085
- Miller M.A., Louie T., Mullane K., Weiss K., Lentnek A., Golan Y., Kean Y., Sears P. Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy. BMC Infect. Dis., 2013, vol. 13: 148. doi: 10.1186/1471-2334-13-148
- Nelson R.L., Suda K.J., Evans C.T. Antibiotic treatment for Clostridium difficile associated diarrhoea in adults. The Cochrane Database Syst. Rev., 2017, vol. 3, no. 3: CD004610. doi: 10.1002/14651858.CD004610.pub5
- Slimings C., Riley T.V. Antibiotics and hospital-acquired Clostridium diffcile infection: update of systematic review and meta-analysis. J. Antimicrob. Chemother., 2014, vol. 69, no. 4, pp. 881–891. doi: 10.1093/jac/dkt477
- WHO. Health topics. Diarrhoea. URL: https://www.who.int/health-topics/diarrhoea#tab=tab_1
补充文件
